Revillion F, Hebbar M, Bonneterre J, Peyrat J P
Laboratoire d'Oncologie Moléculaire Humaine, Centre Oscar Lambret, Lille, France.
Eur J Cancer. 1996 Feb;32A(2):231-4. doi: 10.1016/0959-8049(95)00568-4.
Amplification and overexpression of the C-ERBB2 oncogene have been associated with a poor prognosis and a lower response to chemotherapy in human breast cancer. In this study, plasma c-erbB2 concentrations were determined using an enzyme immunoassay in patients with breast cancer. The links between c-erbB2 concentration and tumoral response to chemotherapy were established. The patients with a c-erbB2 concentration higher than the cut-off value (27 U/ml) were considered as c-erbB2+. Ten of the 33 metastatic breast cancers were c-erbB2+. No statistically significant difference in response to chemotherapy was noted between c-erbB2+ and c-erbB2- patients (4/10 objective responses versus 10/23). Variations in c-erbB2 concentrations during treatment were not related to response to treatment.
C-ERBB2癌基因的扩增和过表达与人类乳腺癌的预后不良及化疗反应较低有关。在本研究中，采用酶免疫测定法测定了乳腺癌患者血浆中的c-erbB2浓度。建立了c-erbB2浓度与肿瘤化疗反应之间的联系。c-erbB2浓度高于临界值（27 U/ml）的患者被视为c-erbB2阳性。33例转移性乳腺癌患者中有10例为c-erbB2阳性。c-erbB2阳性和c-erbB2阴性患者对化疗的反应无统计学显著差异（4/10例客观反应对10/23例）。治疗期间c-erbB2浓度的变化与治疗反应无关。
